Thermo Fisher Scientific (TMO) Equity Income (2021 - 2026)

Thermo Fisher Scientific has disclosed Equity Income across 6 years of filings, most recently posting -$8.0 million for Q1 2026.

• Quarterly Equity Income rose 42.86% year-over-year to -$8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36.0 million (up 54.43% YoY) and the FY2025 annual result came in at -$41.0 million, up 2.38% from the prior year.
• Equity Income grew to -$8.0 million in Q1 2026, from -$32.0 million in the prior quarter.
• Over five years, Equity Income peaked at $33.0 million in Q4 2024 and troughed at -$84.0 million in Q2 2024.
• A 5-year average of -$19.0 million and a median of -$16.0 million in 2023 frame the typical range for Equity Income.
• Annual changes were most pronounced in 2022 — Equity Income plunged 5000.0% — and 2024, when it soared 3400.0%.
• Tracing TMO's Equity Income over 5 years: stood at -$30.0 million in 2022, then surged by 96.67% to -$1.0 million in 2023, then surged by 3400.0% to $33.0 million in 2024, then sank by 196.97% to -$32.0 million in 2025, then soared by 75.0% to -$8.0 million in 2026.
• Business Quant data shows TMO's Equity Income at -$8.0 million in Q1 2026, -$32.0 million in Q4 2025, and $2.0 million in Q3 2025.